|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2004-10-21
|
|
pubmed:abstractText |
We have recently described MAZ51, an indolinone that blocks the ligand-induced autophosphorylation of VEGFR-3, a receptor tyrosine kinase that plays a central role in the regulation of lymphangiogenesis. Here we show that MAZ51 is able to block the proliferation of VEGFR-3-expressing human endothelial cells and is less potently able to induce their apoptosis. MAZ51 also inhibits the proliferation and induces the apoptosis of a variety of non-VEGFR-3-expressing tumor cell lines. These data suggest that MAZ51 blocks the activity of tyrosine kinases in addition to VEGFR-3. In vivo, MAZ51 significantly inhibits the growth of rat mammary carcinomas. These data establish MAZ51 as a compound with antitumor properties that inhibits tumor growth directly and also indirectly by interfering with tumor-host interactions.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3-(4-dimethylamino-naphthalen-1-ylme...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/Naphthalenes,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Tyrosine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, IGF Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Platelet-Derived Growth...,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0020-7136
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2004 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
112
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
986-93
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15386354-Animals,
pubmed-meshheading:15386354-Antineoplastic Agents,
pubmed-meshheading:15386354-Apoptosis,
pubmed-meshheading:15386354-Cell Line, Tumor,
pubmed-meshheading:15386354-Cell Proliferation,
pubmed-meshheading:15386354-DNA, Neoplasm,
pubmed-meshheading:15386354-Endothelial Cells,
pubmed-meshheading:15386354-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:15386354-Female,
pubmed-meshheading:15386354-Humans,
pubmed-meshheading:15386354-Indoles,
pubmed-meshheading:15386354-Lymphangiogenesis,
pubmed-meshheading:15386354-Mammary Neoplasms, Experimental,
pubmed-meshheading:15386354-Naphthalenes,
pubmed-meshheading:15386354-Phosphorylation,
pubmed-meshheading:15386354-Protein-Tyrosine Kinases,
pubmed-meshheading:15386354-Rats,
pubmed-meshheading:15386354-Rats, Wistar,
pubmed-meshheading:15386354-Receptor, IGF Type 1,
pubmed-meshheading:15386354-Receptor, Platelet-Derived Growth Factor beta,
pubmed-meshheading:15386354-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:15386354-Time Factors,
pubmed-meshheading:15386354-Vascular Endothelial Growth Factor Receptor-3
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo.
|
|
pubmed:affiliation |
Forschungszentrum Karlsruhe, Institut für Toxikologie und Genetik, Karlsruhe, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
